2023 ´ëÇѽÉÀåÇÐȸ ¿µÈ£³²Áöȸ ¿¬¼ö°Á : 2023-10-28
±³À°ÀÏÀÚ : 2023-10-28
±³À°Àå¼Ò : ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë(ºÎ»ê¿ª)
±³À°ÁÖÁ¦ : 2023 ´ëÇѽÉÀåÇÐȸ ¿µÈ£³²Áöȸ ¿¬¼ö°ÁÂ
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ¿ï°æÁöȸ
´ã´çÀÚ : ºÎ¿ï°æ½ÉÀåÇÐȸ
¿¬¶ôó : 051-711-6902
À̸ÞÀÏ : sericonf@gmail.com
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 4 ½Ã°£ 25ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í »çÀüµî·Ï¸µÅ© : https://forms.gle/NM2noNWYdzfU9si98
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 13:00~13:15 Side branch protection strategies in Bifurcation PCI ³²Ã¢¿í(°è¸íÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 13:15~13:30 Antithrombotics 1 year after complex PCI in patetints with AF Á¶À翵(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 13:30~13:45 New drugs for managements of dyslipidemia in very high risk AVSCD patients ¹Ú¿ëȯ(â¿ø»ï¼º)
Åä·Ð 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 13:45~14:00 Discussion ¹Ú°æÀÏ,¼Õâ¹è,ÇãÁ¤È£,À±¿ø½Ä,¹Ú±ÙÈ£,½ÉµÎ¼±,±è¿õ,ÀÌÇö»ó,·ùÀç±Ù(µ¿¾Æ´ëº´¿ø,¿ï»ê´ëº´¿ø,°í½Å´ëº¹À½º´¿ø,ÀüºÏ´ëº´¿ø,Á¶¼±´ëº´¿ø,Àü³²´ëº´¿ø,¿µ³²´ëº´¿ø,±¸¹ÌÂ÷º´¿ø,´ë±¸°¡Å縯´ëº´¿ø)
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 14:00~14:15 New concepts in the diagnosis of hypertrophic cardiomyopathy ÀÌÀÚ¿¬(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 14:15~14:30 Advances in assessment of secondary tricuspid regurgitation ³²Á¾È£(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 14:30~14:45 Assessing patients before, during and after treatment in cancer patients ¹ÚÁ¾¿À(ÇØ¿î´ë¹éº´¿ø)
Åä·Ð 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 14:45~15:00 Discussion ¾È¼Èñ,±è°èȯ,ÃÖÁ¤Çö,Àü¼ºÈñ,±èÇö¿í,±èÈ«³â,ÀÌÈñÁ¤,À±Àç¿ë(¿ï»ê´ëº´¿ø,°æ»ó±¹¸³´ëº´¿ø,ºÎ»ê´ëº´¿ø,¿¹¼öº´¿ø,±¤Áֱ⵶º´¿ø,°æºÏ´ëº´¿ø,°è¸í´ëº´¿ø,±¸¹ÌÂ÷º´¿ø)
ÈÞ½Ä 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 15:00~15:15 Break ()
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 15:15~15:30 Novel insights in reflex vasovagal syncope ¾ÈÁøÈñ(ºÎ»ê´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 15:30~15:45 Leadless Pacemakers in Patients With TAVI ±è¼º¼ö(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 15:45~16:00 NOAC use in special situation (CKD, elderly & pregnancy) ȲÁ¾¹Î(°è¸íÀÇ´ë)
Åä·Ð 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 16:00~16:15 Discussion ¹ÚÁ¾¼º,Ȳ±â¿ø,¹Ú¿ëÈÖ,À̱âÈ«,ÀÓ¿µ¹Î,°íÁ¡¼®,Á¶ÇöÁØ,ÀÌÂùÈñ,ÀÌ¿µ¼ö(µ¿¾Æ´ëº´¿ø,¾ç»êºÎ»ê´ëº´¿ø,â¿ø°æ»ó´ëº´¿ø,Àü³²´ëº´¿ø,¼º°¡¸¦·Îº´¿ø,¿ø±¤´ëº´¿ø,´ë±¸ÆÄƼ¸¶º´¿ø,¿µ³²´ëº´¿ø,´ë±¸°¡Å縯´ëº´¿ø)
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 16:15~16:40 Heart failure with supranormal ejection fraction: what evidence do we have? Ȳ¼®Àç(°æ»óÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 16:40~17:05 The role of lung ultrasound for management of heart failure in every day practice ÀÌ´©¸®(Àü³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 17:05~17:30 New drugs for management of HCMP and ATTR amylodosis ±è⿬(´ë±¸Ä«Å縯)
Åä·Ð 10¿ù 28ÀÏ ¾Æ½ºÆ¼È£ÅÚ 22Ãþ ±×·£µåº¼·ë 17:30~17:40 Discussion ±è¼öÁø,¼Á¤¼÷,±èÁ¤¼ö,¼ÛÁöÀº,ÃÖ°¡Èñ,¹èÁØÈ£,Á¤ÇØ¿ø,ÀÌÁ¤Àº(°í½Å´ëº¹À½º´¿ø,ÀÎÁ¦´ëºÎ»ê¹éº´¿ø,¾ç»êºÎ»ê´ëº´¿ø,¿¹¼öº´¿ø,Àü³²´ëº´¿ø,Æ÷Ç×¼¼¸í±âµ¶º´¿ø,´ë±¸°¡Å丯´ëº´¿ø,°è¸í´ëº´¿ø)